Clinical Manifestations in Patients with Genotypes 1 and 3 of Viral Hepatitis C, Depending on the Severity of Liver Fibrosis

Aim: to compare the clinical manifestations in patients with genotypes 1 and 3 of viral hepatitis C (HCV) depending on the severity of liver fibrosis (LF).

Study Design: a comparative study of randomized groups of patients treated in an inpatient or outpatient setting.

Materials and methods. A total of 297 patients with HCV genotype 1 and 231 patients with HCV genotype 3 were examined. The diagnosis of chronic viral hepatitis C was established according to the recommendations of the European Association for the Study of the Liver. All patients underwent clinical and biochemical blood tests, ultrasound examination of the liver and pancreas. LF was studied by shear wave transient elastometry with METAVIR score.

Results. Severe LF was associated in both groups of patients with an increase in the frequency of liver complaints, hepatomegaly and splenomegaly, an increase in the content of bilirubin and alanine aminotransferase in the blood, a decrease in the number of platelets and the concentration of albumin in the blood. Only in patients with HCV genotype 3 was an increase in viral load and a trend towards a decrease in the proportion of neutrophils in the blood in patients with stages 3–4 LF compared with 0–2 stages of LF according to METAVIR.

Conclusion. We think that the explanation for the higher incidence of severe LF in patients with HCV genotype 3 is probably a more significant deformation of the immune response, leading to an increase in viral load and an aggressive course of pathology.

1. Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol. Hepatol. 2022;7(5):396–415. DOI: 10.1016/S2468-1253(21)00472-6

2. Ghany M.G., Morgan T.R.; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71(2):686–721. DOI: 10.1002/hep.31060

3. Younossi Z., Papatheodoridis G., Cacoub P. et al. The comprehensive outcomes of hepatitis C virus infection: a multi-faceted chronic disease. J. Viral. Hepat. 2018;25(Suppl. 3):6–14. DOI: 10.1111/jvh.13005

4. Borgia S.M., Hedskog C., Parhy B. et al. Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. J. Infect. Dis. 2018;218(11):1722–1729. DOI: 10.1093/infdis/jiy401

5. Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitisC treatment-inducedviralclearance.Nature.2009;461(7262):399–401. DOI: 10.1038/nature08309

6. Thrift A.P., El-Serag H.B., Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat. Rev. Gastroenterol. Hepatol. 2017;14(2):122–132. DOI: 10.1038/nrgastro.2016.176

7. Batskikh S.N., Morozov S.V., Chulanov V.P., Pokrovsky V.I. Hepatitis C virus genotype 3: that simple, yet that complex. Terapevticheskiy arkhiv. 2012;84(11):4–10. (in Russian)

8. Silini E., Bono F., Cividini A. et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology. 1995;21(2):285–290. DOI: 10.1002/hep.1840210204

9. Shchanitcyna S.E., Burnevich E.Z., Nikulkina E.N. et al. Risk factors of unfavorable prognosis of chronic hepatitis C. Terapevticheskiy arkhiv. 2019;91(2):59–66. (in Russian). DOI: 10.26442/00403660.2019.02.000082

10. Shahnazarian V., Ramai D., Reddy M., Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann. Gastroenterol. 2018;31(5):541–551. DOI: 10.20524/aog.2018.0281

11. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J. Hepatol. 2017;66(1):153–194. DOI: 10.1016/j.jhep.2016.09.001

12. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 2018;69(2):461–511. DOI: 10.1016/j.jhep.2018.03.026

13. Ludwig J. Terminology of chronic hepatitis, hepatic allograft rejection, and nodular lesions of the liver: summary of recommendations developed by an international working party, supported by the World Congresses of Gastroenterology, Los Angeles, 1994. Am. J. Gastroenterol. 1994;89(8 Suppl.):S177-S181.

14. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–832. DOI: 10.1016/s0140-6736(96)07642-8

15. Hayes C.N., Imamura M., Tanaka J., Chayama K. Road to elimination of HCV: Clinical challenges in HCV management. Liver Int. 2022;42(9):1935–1944. DOI: 10.1111/liv.15150

16. Isakov V., Nikityuk D. Elimination of HCV in Russia: Barriers and Perspective. Viruses. 2022;14(4):790. DOI: 10.3390/v14040790

17. Russo F.P., Zanetto A., Pinto E. et al. Hepatocellular carcinoma in chronic viral hepatitis: where do we stand? Int. J. Mol. Sci. 2022;23(1):500. DOI: 10.3390/ijms23010500

18. Singal A.G., Lampertico P., Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J. Hepatol. 2020;72(2):250–261. DOI: 10.1016/j.jhep.2019.08.025

19. McGlynn K.A., Petrick J.L., El-Serag H.B. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73 (Suppl. 1):4–13. DOI: 10.1002/hep.31288

20. Ahumada A., Rayón L., Usón C. et al. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? World J. Gastroenterol. 2021;27(40):6737–6749. DOI: 10.3748/wjg.v27.i40.6737

21. Zhuang L., Li J., Zhang Y. et al. Real-world effectiveness of direct-acting antiviral regimens against Hepatitis C Virus (HCV) genotype 3 infection: a systematic review and meta-analysis. Ann. Hepatol. 2021;23:100268. DOI: 10.1016/j.aohep.2020.09.012

22. Probst A., Dang T., Bochud M. et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. J. Viral. Hepat. 2011;18(11):745–759. DOI: 10.1111/j.1365-2893.2011.01481.x

23. Elsheikh M.E.A., McClure C.P., Tarr A.W., Irving W.L. Sero-reactivity to three distinct regions within the hepatitis C virus alternative reading frame protein (ARFP/core+1) in patients with chronic HCV genotype-3 infection. J. Gen. Virol. 2022;103(3):001727. DOI: 10.1099/jgv.0.001727

24. Abulitifu Y., Lian J., Adilijiang M. et al. Effectiveness and safety of sofosbuvir-velpatasvir in patients with cirrhosis associated with genotype 3 hepatitis C infection in Xinjiang, China. Infect. Drug. Resist. 2022;15:6463–6470. DOI: 10.2147/IDR.S385071

25. Loo J.H., Xu W.X.F., Low J.T. et al. Efficacy and safety of sofosbuvir/ velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: a meta-analysis. World J. Hepatol. 2022;14(6):1248–1257. DOI: 10.4254/wjh.v14.i6.1248

26. McCombs J., Matsuda T., Tonnu-Mihara I. et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern. Med. 2014;174(2):204–212. DOI: 10.1001/jamainternmed.2013.12505

27. Wu N., Rao H.Y., Yang W.B. et al. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chin. Med. J. (Engl). 2020;133(3):253–261. DOI: 10.1097/CM9.0000000000000629